Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

February 21, 2019

Sosei Heptares doses first patient in trial targeting endocrine disorders

Sosei Group announced that the first healthy subject has been dosed with a small molecule HTL0030310 in a Phase I clinical study, marking the start of a new in-house clinical program targeting endocrine disorders, including Cushing’s disease.

Sosei Heptares doses first patient in trial targeting endocrine disorders